Bayer, Onyx win early FDA OK for Nexavar in thyroid cancer
This article was originally published in Scrip
Executive Summary
Christmas came early for Bayer HealthCare's and Onyx Pharmaceuticals, now a subsidiary of Amgen, with the FDA's 22 November approval of Nexavar (sorafenib) as a treatment for patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer – the first drug to gain the indication.